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Karolinska Institutet, SwedenVariants in the PLPP3 gene encoding for lipid phosphate
phosphohydrolase 3 have been associated with susceptibility
to atherosclerosis independently of classical risk factors.
PLPP3 inactivates lysophosphatidic acid (LPA), a pro-inflam-
matory, pro-thrombotic product of phospholipase activity.
Here we performed the first exploratory analysis of PLPP3,
LPA, and LPA receptors (LPARs 1–6) in human atheroscle-
rosis. PLPP3 transcript and protein were repressed when
comparing plaques versus normal arteries and plaques from
symptomatic versus asymptomatic patients, and they were
negatively associated with risk of adverse cardiovascular
events. PLPP3 localized to macrophages, smooth muscle,
and endothelial cells (ECs) in plaques. LPAR 2, 5, and espe-
cially 6 showed increased expression in plaques, with LPAR6
localized in ECs and positively correlated to PLPP3. Utilizing
in situ mass spectrometry imaging, LPA and its precursors
were found in the plaque fibrous cap, co-localizing with
PLPP3 and LPAR6. In vitro, PLPP3 silencing in ECs under
LPA stimulation resulted in increased expression of adhesion
molecules and cytokines. LPAR6 silencing inhibited LPA-
induced cell activation, but not when PLPP3 was silenced
simultaneously. Our results show that repression of PLPP3
plays a key role in atherosclerosis by promoting EC activation.
Altogether, the PLPP3 pathway represents a suitable target for
investigations into novel therapeutic approaches to ameliorate
atherosclerosis.Received 10 April 2018; accepted 13 May 2018;
https://doi.org/10.1016/j.omtm.2018.05.003.
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Therapies that can reduce the deposition of apolipoprotein-B-con-
taining lipoproteins in lesion-susceptible arterial segments can slow
down atherosclerotic cardiovascular disease (ACVD) progress.1 Effi-
cient therapies for suppression of the inflammatory response, whichMolecular Therapy: Methods & Clin
This is an open access article under the CC BY-NCaccompanies lipoprotein deposition and contributes to plaque devel-
opment and ACVD,may add further cardiovascular benefit, as shown
recently with the CANTOS (Canakinumab Anti-inflammatory
Thrombosis Outcomes Study) clinical trial.2
Several genome-wide association studies (GWASs), including a meta-
analysis, have identified PLPP3, the gene encoding lipid phosphate
phosphatase 3, as a candidate locus causally related to ACVD
risk.3,4 Furthermore, PLPP3 SNP rs17114036 was included in a ge-
netic risk score (GRS) study showing that individuals with high
GRSs appear to have a larger benefit in cardiovascular absolute risk
reduction from statin treatment than those with low GRSs,5 thus sug-
gesting that PLPP3 genetic data may be applied to enhance clinical
benefit with already established therapy for ACVD. We identified
PLPP3 and the associated lysophosphatidic acid (LPA) axis as
possible anti-atherosclerotic drug candidates after applying a target
selection workflow within the CarTarDis Consortium (http://
cartardis.eu), aimed at identifying targets suitable for pharmaceutical
drug development. In our approach, candidate targets were first
assembled from published data related to human genetics of CVD,
and subsequently they were prioritized using stringent target discov-
ery filters, including genetic correlation to ACVD clinical phenotypes,
novelty, feasibility to validate (in vitro and in vivo), and relation to
known ACVD mechanisms.6ical Development Vol. 10 September 2018 ª 2018 The Authors. 17
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Methods & Clinical DevelopmentPLPP3 enzyme is an integral membrane protein that dephosphory-
lates and inactivates various lipid-phosphate mediators, such as
LPA and sphingosine-1-phosphate, thus blocking the downstream
signals of these bioactive lipids.7 Expression quantitative trait locus
(eQTL) analyses linked the major ACVD risk-associated allele with
lower expression of PLPP3 in human endothelial cells (ECs), but
not in other tissues.8,9 These results suggest that ACVD risk-associ-
ated SNPs may increase the disease susceptibility by regulating
PLPP3 expression in an endothelial-specific manner. Elegant mouse
in vitro and in vivo studies have shown that PLPP3 expression in
the arterial wall is modulated by hemodynamic forces and that it is
involved in arterial wall pathology by modulating vascular cell func-
tions.9–11 Mechanistic studies with isolated arterial cells showed that
lower expression of PLPP3 sensitizes the response of ECs to LPA.9,12
Several studies have shown that LPA accumulates in human atheroma
where it can exert pro-thrombotic effects.13,14 LPA is an amphipatic
phospholipid that can interact with cell membranes by its detergent
properties but also by its association to LPA-specific receptors
(LPARs 1–6).15 Experimental evidence supports a role for LPA and
its G-protein-coupled receptors in promoting pro-atherogenic, pro-
inflammatory, and pro-thrombotic processes.16,17 LPA in lesions
can be generated by enzymatic hydrolysis of lysophospholipids by
extracellular lysophospholipase D, autotaxin, and by local deposition
of modified apoB-lipoprotein carriers of LPA and its phospholipid
precursors.7,18,19 For example, phosphatidylcholine (PC) (34:1) and
PC (34:2) are two PC species connected to the lysophosphatidylcho-
line (LPC), which are the degradation products from PC hydrolysis by
phospholipases and precursors for LPA production. LPA molecules
can be inactivated by the enzymatic action of PLPP3, which removes
the phosphate group generating the corresponding alcohols that are
not agonists for LPA receptors (LPARs).20 Thus, PLPP3 expression
levels in the arterial wall may have a relevant function in disease pro-
gression by affecting local LPAR-LPA-mediated signaling.
To explore the putative association of the PLPP3-LPAR(s) pathway
with ACVD and its potential for drug development, we performed
a comprehensive analysis on genetic, transcriptomic, and proteomic
levels in human carotid plaques and normal arteries (NAs). In the
same tissues, we also evaluated their possible co-localization with
LPA and its phospholipid precursors. In-vitro-silencing experiments
were conducted to characterize the role of PLPP3 and LPARs on
endothelial activation. Our results from investigation of this human
genetic association and the pathway biology as amarker of atheroscle-
rosis provide insight for selection and identification of potential new
therapeutic approaches to prevent ACVD and its complications.
RESULTS
PLPP3 Is Repressed in Human Carotid Atherosclerotic Lesions
We first evaluated the genetic association of a previously reported
rs17114036 variant with PLPP3 levels in human plaques by eQTL
analyses. Two suitable proxies were identified (rs6588634 and
rs9970807, both R2 > 0.8 and D’ = 1) that confirmed a marginal asso-
ciation with PLPP3 mRNA levels in plaques from n = 127 patients18 Molecular Therapy: Methods & Clinical Development Vol. 10 Septemthat were available for these analyses (p = 0.07; Figure 1A). Next,
gene expression analysis of totally n = 177 lesions showed a significant
downregulation of PLPP3 transcript in carotid plaques (CPs)
compared to macroscopically NAs in two non-overlapping microar-
ray datasets (n = 127 CP versus n = 33 NA from the larger discovery
dataset and n = 50 CP plaque versus n = 5 NA from the smaller vali-
dation dataset; Figure 1B), with mean log2 difference ± SD =
0.6311 ± 0.1731 and mean log2 difference ± SD = 1.012 ±
0.3323, respectively. Notably, PLPP3 mRNA was also significantly
downregulated in CPs from symptomatic patients compared with
asymptomatic ones (mean difference ± SD = 0.2803 ± 0.1031).
Importantly, these data were confirmed on the protein level by
mass spectrometry analyses comparing plaques with adjacent control
arterial tissue (n = 18 matched samples) and plaques from symptom-
atic versus asymptomatic patients (n = 9 in each group; Figure 1C),
strongly suggesting a correlation between lower PLPP3 levels and a
more severe clinical phenotype. Moreover, patients with below-me-
dian expression levels of PLPP3 in their plaques at surgery conferred
a significantly higher risk of future adverse cardio- and cerebrovascu-
lar events during the follow-up period after carotid endoarterectomy
(CEA) (p = 0.0072; Figure 1D).
To begin delineating the cellular processes associated with PLPP3
expression, correlation analyses were performed in plaques from
the Biobank of Karolinska Endarterectomies (BiKE) discovery dataset
between PLPP3 and various cellular markers (Table S1). These ana-
lyses showed positive correlation (Pearson r > 0.3, p < 0.0001) be-
tween PLPP3 expression and typical smooth muscle cell (SMC)
markers; endothelial marker CD31; T lymphocyte marker CD45RA;
pro-inflammatory markers nuclear factor kB (NF-kB) and BMP4;
extracellular matrix degradation via SULF1; growth factors TGFB1,
IGF1, PDGFB, and PDGFD; and chemokine CCR2. Weak positive
correlations were found also with some macrophage markers.
To evaluate these bioinformatic results, we further examined PLPP3
mRNA and protein expression levels and localization in various cell
types in NAs and plaques in situ. Overall, PLPP3 protein signal was
strong in NAs, particularly in CD31+ ECs, but it was also found in
medial SMCs (Figure 2A). PLPP3 transcript and protein (Figure 2B)
expression was also detected in CPs (n = 10 samples examined),
particularly localized in the fibrous cap and in the areas lining the
necrotic core. PLPP3 was absent from peripheral, subintimal plaque
areas. Double immunostaining with specific cell markers showed
PLPP3 protein localization in various cell types, such as SMCs
(SMA+), ECs (CD31+), and macrophages (CD68+; Figure 2B), con-
firming the correlation analyses. These results confirmed overall
lower levels of PLPP3 in advanced human plaques, but they indi-
cated a wide expression pattern linked to several major plaque cell
types.
LPAR6 Is the Most Abundantly Expressed LPAR in Human
Plaques, Localized to ECs, and Positively Correlatedwith PLPP3
Expression of LPAR1–6 transcripts was then analyzed in microarrays
from human CPs compared to NAs (discovery dataset) (Figure 3).ber 2018
Figure 1. Genetic Association and Expression of
PLPP3 in Advanced Human Atherosclerotic Plaques
(A) Genetic variant rs17114036was found to be tentatively
associated with PLPP3 mRNA expression in carotid pla-
ques by expression quantitative train locus (eQTL) analysis
of two suitable proxies in n = 127 patients. Plots show
median ± SD. (B) Two microarray datasets (discovery set
on the left and validation set on the right) showing the
PLPP3 mRNA expression in carotid plaques (CPs)
compared to normal arteries (NAs), along with the com-
parison between plaques from symptomatic (S) and
asymptomatic (AS) patients. Discovery set contained
n = 33 NAs and n = 127 CPs and validation set contained
n = 5 NAs and n = 50 CPs. Values are expressed as log2
mean ± SD. *p < 0.05 and ***p < 0.001; ns, not significant.
(C) Evaluation of PLPP3 protein levels by mass spec-
trometry comparing plaques (CPs) with adjacent control
arterial tissue (n = 18matched samples), and plaques from
S versus AS patients (n = 9 per group). Values are ex-
pressed in a.u. as mean ± SD. (D) Survival curves illus-
trating MACCE-free survival of patients during the follow-
up period after surgery, based on PLPP3 mRNA expres-
sion in BiKE plaques above (black) and below (red) the
median values (x axis, days of event-free survival). Each
mark along the lines indicates an event. Total number of
events in the cohort was n = 58. MACCE, major adverse
cerebro- and cardiovascular event.
www.moleculartherapy.orgLPAR1 was the only one downregulated in the CP versus NA compar-
ison (mean log2 difference ± SD = 1.836 ± 0.1106), while LPAR4
did not show any significant difference and was detected at low levels,
similar to LPAR3. LPARs 2, 5, and 6 were all significantly upregulated
in this comparison and showedmoderate-to-high expression levels in
plaques, particularly LPAR6 (mean log 2 difference ± SD, LPAR2 =
1.037 ± 0.0876, LPAR5 = 1.604 ± 0.1306, and LPAR6 = 1.032 ±
0.1268).
Expression correlations of LPARs with markers of cell types and pro-
cesses in plaques showed an association between LPAR1 and typical
SMC markers, whereas LPAR2 was negatively correlated with SMCs
and showed moderate positive correlation with inflammatory cells
(T lymphocytes and macrophages). Correlation analyses for LPAR3
and LPAR4 were inconclusive, likely due to low expression levels of
these receptors in the tissue. LPAR5 and LPAR6 correlated to endo-
thelial and inflammatory cell markers (dendritic cells, T lymphocytes,
and macrophages) (Table S2).Molecular Therapy: Methods & ClinThese analyses were followed by in situ hy-
bridization (ISH) and immunohistochemistry
(IHC) of the LPARs in consecutive sections
of human lesions, which generally confirmed
the differential expression data and correla-
tion pattern of the receptors (Figure S1).
LPAR1 was detected at low levels while
LPARs 3 and 4, in line with the low expression
levels from gene arrays, could not be detectedin plaques (data not shown). LPAR2 localized exclusively in in-
flammatory cells, as determined by double staining with CD3,
CD8, CD68, and CD163 (Figure S2). LPAR6 showed the most
abundant expression of all receptors, both by ISH (Figure 4A)
and IHC (Figure 4B), with localization in CD34+ ECs and in the
fibrous cap smooth muscle-like cells. Together our analyses on
transcript and protein levels showed the differential expression
of LPARs in human plaques, and they revealed a strong enrich-
ment of primarily LPAR6, but also LPAR2 and LPAR5 to a lesser
extent.
Next, the relationship between PLPP3 and LPARs in plaques was as-
sessed by expression correlations from microarrays (Table S3). These
analyses indicated a significantly positive association of PLPP3 with
LPAR6 and negative association with LPAR2 (Figure 5A). Non-sig-
nificant correlations were found between PLPP3 and other LPARs.
A combined ISH/IFL staining was thus performed for PLPP3 and
LPAR6 in human early fibroatheroma lesions, including markers ofical Development Vol. 10 September 2018 19
Figure 2. Localization of PLPP3 in Normal Arteries
and Carotid Plaques
(A) Immunohistochemical staining shows the distribu-
tion of PLPP3 (red signal) in normal human artery, in
medial smooth muscle cells, and CD31+ (green signal)
luminal endothelial cells. (B) In situ hybridization detec-
tion of PLPP3 mRNA transcript in human lesions (top
raw). Arrows indicate the RNA probe signals (also
shown in the zoomed inset). Immunohistochemical
stainings show the distribution of PLPP3 in human
plaques. Double staining shows the co-localization of
PLPP3 (red signal) with endothelial cell marker (CD31,
green signal), smooth alpha actin (SMA, green signal),
and macrophage cell marker (CD68, green signal). Ar-
rows indicate double-positive cells and insets show
higher magnification. Images were taken with the 40
objective.
Molecular Therapy: Methods & Clinical DevelopmentECs and SMCs. These experiments convincingly showed that both
PLPP3 and LPAR6 mRNA localize in CD34+ ECs on the luminal
side of the fibrous cap, and localization in SMCs could also be
confirmed (Figures 5B and 5C).20 Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018PLPP3, LPAR6, and LPA Pathway-Related
Lipids Co-localize in Plaques
To examine the spatial relationship among
PLPP3, LPAR6, and lipid species that constitute
PLPP3 substrates in human plaques, a combi-
nation of immune- and lipid-imaging in situ
was employed (n = 4 CPs tested). First, ten
lipid species between 400 and 800 Da were de-
tected in plaques (Table S4). Replicates of
MALDI-mass spectrometry imaging (MSI) in
detection mode at 30 mm showed the presence
of cholesteryl ester (CE) stearate (18:0); oleate
(18:1), and linoleate (18:2), localized particu-
larly in the necrotic core and upper border of
the fibrous cap. PC, the main phospholipid
type, was detected in the necrotic core and in
the middle area of the fibrous cap. LPC stearic
acid (18:0), oleic acid (18:1), and linoleic acid
(18:2) were mainly detected in the fibrous cap
and shoulder region lining the necrotic core
(Figure S3).
PLPP3 is an enzyme that de-phosphorylates
LPA into monoacylglycerol (MAG); therefore,
we next sought to examine the spatial relation-
ship among PLPP3, LPAR6, and LPA in pla-
ques. We could show that positive PLPP3 im-
munodetection (Figure 6A) co-localized with
a high-intensity signal for LPA, a PLPP3 sub-
strate, but not with PA signal, an LPA precur-
sor (Figure 6B and overlay in Figure 6C). Simi-larly, co-localization was observed between LPAR6 and LPA, an
LPAR ligand, but not with PA. Moreover, LPA and PA appeared
to be mutually anti-localized based on the low spatial correlation
factor of r = 0.2.
Figure 3. LPAR Expression in Comparison between
Normal Arteries and Plaques
mRNA levels of LPA receptors (LPARs 1–6) in normal
arteries (n = 33) and in human plaques (n = 127) were
interrogated in the BiKE discovery microarray dataset.
Values are expressed as log2 mean ± SD. *p < 0.05, and
****p < 0.0001; ns, not significant.
www.moleculartherapy.orgSilencing of LPAR6 Diminishes LPA-Induced Endothelial
Activation In Vitro, but Not after PLPP3 Silencing
The possible effect of a reduced PLPP3 expression in ECs, which
would resemble that observed in human plaques, was assessed using
small interfering RNA (siRNA)-mediated gene silencing. Silencing of
PLPP3 in human umbilical vein ECs (HUVECs) (by 47% as
compared with a non-targeting scramble siRNA) resulted in a signif-
icant increase in mRNA expression of pro-inflammatory cytokines
MCP-1 and interleukin-6 (IL-6) as well as the adhesion molecules
VCAM-1 and ICAM-1 (Figure 7A). Importantly, a similar effect of
PLPP3 silencing was previously reported in human aortic ECs.9,12
Together, these results supported the anti-inflammatory function of
PLPP3 in ECs.
To further explore this finding, we next stimulated the HUVECs
with LPA, which led to the increased expression of cytokines
IL-6 and MCP-1 as well as ICAM-1 and VCAM-1 (Figure 7B).
These effects were comparable to when PLPP3 was silenced, which
again suggested that lower PLPP3 levels may cause endothelial
activation through enhanced LPA signaling. We further hypothe-Molecular Therapy: Methods & Clinsized that the effect of LPA would be medi-
ated via LPAR6, shown to be the most prom-
inent LPAR expressed in ECs in human
plaques from our cohort. Interestingly,
silencing of LPAR6 in HUVECs (by 57% on
an mRNA level and confirmed also on a
protein level; Figure S4) inhibited LPA-
induced endothelial activation, observed by
the reduced expression of ICAM-1, VCAM-
1, IL-6, and MCP-1 (Figure 7B).
Surprisingly, simultaneous silencing of both
LPAR6 and PLPP3 did not result in any
diminishing effects on endothelial activation
compared to those observed after silencing
PLPP3 alone (Figure 7C). In addition, expres-
sion of LPAR1 was enhanced after silencing of
LPAR6 and LPA stimulation, but not when in
combination with the silencing of PLPP3. The
mRNA expression of other LPARs (LPAR2, 4,
and 6) was not significantly affected by the
knockdown of PLPP3, and LPAR3 and LPAR5
were undetectable in ECs (data not shown).
LPAR2 was only upregulated after the stimula-tion with LPA, and this effect could be inhibited by the silencing of
LPAR6.
DISCUSSION
To the best of our knowledge, this is the first study to systematically
characterize the expression of the PLPP3 pathway, including all six
LPARs as well as substrate LPA and its precursors phosphatidic acid
(PA) and LPC, in advanced human atherosclerotic plaques. A reduced
PLPP3 mRNA and protein expression was demonstrated in human
plaques comparedwith normal disease-free artery specimens, suggest-
ing more permissive conditions for signaling through LPA and its re-
ceptors in late-stage human atherosclerosis. This assumption was
further supported by indications of even lower levels of PLPP3 in pla-
ques from symptomatic patients than in those of asymptomatic ones,
and an inverse relationship between plaque PLPP3 levels and future
adverse cardio- and cerebrovascular events. Together with our
eQTL studies confirming the genetic link between PLPP3 and carotid
atherosclerosis, these findings suggest that suppression of PLPP3 is
associated with more severe disease and confirm a potential athero-
protective role for the enzyme, as previously proposed.9ical Development Vol. 10 September 2018 21
Figure 4. Localization of LPAR6 in Plaques
(A) In situ hybridization detection of LPAR6 mRNA tran-
script in human lesions. Arrows indicate the RNA probe
signals (red). (B) Immunohistochemistry staining of LPAR6
in plaque (red signal) depicts its strong overall expression
and localization in cells lining the luminal wall of the fibrous
cap (arrows) as well as in the underlying cells with elon-
gated nuclei. Nuclei (purple) are stained with hematoxylin.
Images were taken with 20, 40, and 63 objectives.
Molecular Therapy: Methods & Clinical DevelopmentThis study is thefirst to definitively localize LPAandPAmolecular spe-
cies in situ in the fibrous cap of human plaques using MSI and overlay
with PLPP3 and LPAR6 by immunodetection. Our analyses showed
that PLPP3 and LPAR6 protein in the fibrous cap co-localize with
LPA, the substrate of PLPP3 and the ligand for LPAR6, but not with
PA that is a potential precursor of LPA generated by A-type phospho-
lipase activity. Lipoprotein associated phospholipase A2 (Lp-PLA2), a
platelet-activating factor (PAF) acetyl-hydrolase or group VII phos-
pholipase A-secreted enzyme that catalyzes the degradation of PAF-
producing LPA and acetate, could be a source of LPA. However, in a
large-scale human genetic study, none of a series of Lp-PLA2-lowering
alleles, including a loss-of-function mutation leading to full Lp-PLA2
deficiency, was related to coronary heart disease risk, suggesting that
Lp-PLA2 is unlikely to be a causal risk factor for ACVD.
21 This conclu-
sion is also supported by the lack of cardiovascular benefit of the anti-
PAFAH/Lp-PLA2 drug darapladib in large phase three clinical trials.
22
Thus, we suggest that other extra- and intracellular enzymatic path-
ways may be involved in the local production of LPA independent of
Lp-PLA2 activity.
23 We identified saturated LPC (LPC18:0) as the
main LPC species present in the advanced atherosclerotic lesions, con-
firming the previous findings that showed the presence and the enzy-
matic activity of secretory phospholipase A2 in human lesions.24 LPC
associated with plasma lipoproteins accumulating in lesions can be
another source of local LPC species.25 LPAhas been reported by others
to be significantly higher in coronary than in peripheral systemic arte-
rial blood.14 Thus, together with our results, these findings support the
hypothesis that higher concentrations of LPAmight be associated with
atherogenesis and its clinical consequence, ACVD.
LPA is a potent lipid mediator with broad cellular effects that are rele-
vant to athero-thrombosis.13,26,27 PLPP3 deactivates LPA, and it has22 Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018been suggested that the enhancement of its
expression and activity might serve for phar-
macological therapeutic purposes; however,
considering that its control mechanisms are
not yet understood, this could be a challenging
task. An alternative approach to reduce LPA-
mediated pro-inflammatory activation could
be to target LPA-mediated signaling through
modulation of its different receptors (LPARs).
However, this requires a detailed investigation
of the expression and cellular distribution of
LPARs and other components of the pathwayin human atherosclerosis, and our results should be considered as
an initial step in this area.
Our investigation suggests that the repression of PLPP3 in atheroscle-
rotic arterial tissue could contribute to the elevated local accumula-
tion of LPA and increase its biological effects in lesions. It should
be noted that PLPP3 fulfills also non-catalytic functions, such as its
interaction with integrins that can promote EC-to-cell adhesion.28
Although PLPP3 expression levels are lower in plaques, we showed
that the residual protein localizes to ECs, SMCs, and CD68+ cells.
However, further studies will be needed to establish whether differen-
tial expression of PLPP3 in normal and diseased tissue is translated
into differences in the hydrolytic activity required for deactivation
of LPA. Similarly, we do not know if increased expression of the
enzyme affects its non-enzymatic roles in endothelium and foam
cells.29
When it comes to the LPARs, our results indicated that LPAR2,
LPAR5, and especially LPAR6 were the most prominent receptors ex-
pressed in lesions. LPAR2 and LPAR6 were the only receptors also
showing significant correlation with PLPP3 expression at the
mRNA level. We found that LPAR6 expression was mostly associated
with luminal ECs and with SMCs, but less frequently with inflamma-
tory cells. Interestingly, LPAR6 has previously been involved in LPA-
induced actin stress formation in ECs.30 LPAR2 was expressed
in a specific subset of inflammatory cells, thus, it is possibly
limited to certain types of plaques that express less PLPP3 combined
with increased leukocyte content. These results are in line with
previous data indicating that LPA can stimulate T cell migration
and secretion of matrix metalloproteinases when overexpressing
LPAR2.31 Together, this suggests that LPAR2 might contribute to
Figure 5. Association between PLPP3 and LPAR6 in Human Lesions
(A) Correlation plot showing significantly positive association of PLPP3 with LPAR6
mRNA expression levels in plaques, while inverse with LPAR2. Pearson correlation
calculated based on the discovery dataset (n = 127 samples). (B and C) Localization
of (B) PLPP3 and (C) LPAR6mRNA in CD34+ endothelial and SMA+ smooth muscle
cells in the fibrous cap, shown by combined in situ hybridization (red signal) and
immunofluorescence (green signal) in human early fibroatheroma lesions. Nuclei are
stained with DAPI. Images were taken with 20 objective. IFL, immunofluores-
cence.
www.moleculartherapy.orgLPA-mediated atheroma progression and may be a promising LPAR
for pharmacological intervention to reduce atherogenic inflamma-
tion. With respect to the other LPARs, we found that the expression
of LPARs 3 and 4 was either absent or too low to be detected both inMolecular Thplaques and specifically in ECs, indicating that these receptors may be
of limited importance in the regulation of LPA activation in athero-
sclerotic lesions.
Our in vitro experiments were targeted to ECs as a plausible cell
type to facilitate the future therapeutic application of the PLPP3
pathway. We show that silencing of PLPP3 did not affect the
expression levels of LPARs 1, 2, 4, and 6 in ECs, although there
was a significantly positive correlation between PLPP3 and
LPAR6 in the whole-plaque tissue. This suggests a mechanism by
which the loss of PLPP3 expression, and the potential subsequent
increase in LPA, does not lead to a compensatory increase in the
expression of LPARs in ECs. Knockdown of LPAR6 appeared to
inhibit the upregulation of LPAR2 after LPA stimulation, which in-
dicates that the LPA-LPAR6 interaction may be involved not only
in endothelial activation but also in the regulation of LPAR2.
Furthermore, the inhibition of LPAR6 induced the expression of
LPAR1, suggesting a compensatory mechanism between these
two receptors in ECs. Based on our in vitro data, it is possible to
speculate that, although silencing of PLPP3 and LPA stimulation
induce similar phenotypes in ECs, they may not share the same
LPA-LPAR6 signaling. Our results also indicate a complexity and
flexibility in signaling patterns among LPARs that can be dictated
by repression of PLPP3 in combination with some yet unknown
factors in the atherosclerotic tissue environment, considering that
silencing of LPAR6 did not have a diminishing effect on the endo-
thelial activation already observed after silencing of PLPP3 alone.
Further experiments are needed to better understand the interac-
tion among PLPP3, LPA, and the different LPARs.
Limitations
Although the BiKE cohort is one of the world’s largest when it comes
to the molecular profiles of human carotid atherosclerotic plaques,
an even larger number of subjects may be necessary to validate
our findings in independent biobanks and generalize the observa-
tions to other vascular beds. Replication is warranted in heteroge-
neous cohorts that will permit adjustment for traditional cardiovas-
cular risk factors and evaluation within subgroups of interest, such
as defined by age, gender, symptoms, and comorbidities. This is
also important in the context of genetic investigations of PLPP3
and LPARs. Consensus is lacking in the field regarding the selection
of appropriate control tissues, and it is worth noting that arteries of
various embryonic origins have been used for this purpose as well as
adjacent macroscopically intact parts of lesions. In addition, more
detailed in vitro studies were precluded due to the lack of suitable
PLPP3 antibodies that would allow assessment of the protein levels.
Finally, molecular mechanisms behind the interactions among
PLPP3, LPA, and LPARs that could modulate atherosclerosis need
to be explored beyond in vitro findings, using atherosclerotic animal
models.
Conclusions
We found that PLPP3 is repressed in the advanced stages of human
atherosclerosis compared with NAs. The enzyme co-localizes inerapy: Methods & Clinical Development Vol. 10 September 2018 23
Figure 6. Relationship of PLPP3, LPAR6, and LPA
Pathway-Related Lipids in Atherosclerotic Plaques
(A) Double immunostaining of PLPP3 (red) and LPAR6
(green) in atherosclerotic plaques, showing their co-
localization and accumulation of positive signal in the
fibrous cap and shoulder region. (B) Distribution of lyso-
phosphatidic acid (LPA 18:0, to the left) and PA 36:2 (to
the right) on consecutive plaque sections by mass
spectrometry imaging (MSI). Red signal indicates the
highest amount of detected lipid (color scale reported in
the middle). (C) Overlay of the PLPP3 and LPAR6 staining
by IHC with MSI for LPA (left panel) or PA (right panel),
showing an increase of LPA and a decrease of PA in
PLPP3/LPAR6 double-positive regions. Images were
taken with 2 objective, representative of n = 4 inde-
pendent experiments.
Molecular Therapy: Methods & Clinical Developmentlesions mainly with LPARs 5 and 6. Furthermore, expression of
LPARs is high in the atheroma, and LPA co-localizes within plaque
regions where the cells expressing PLPP3 and LPAR6 are also found.
Collectively, our findings indicate that LPA-mediated inflammatory
cascades are relevant in the pathophysiology of human atheroscle-
rosis and that the PLPP3 enzyme and LPARs canmodulate the poten-
tial atherogenicity of LPA signaling.
Clinical Impact
Altogether, our results support the hypothesis that PLPP3 serves to
suppress inflammatory pathways in atherosclerotic plaques and that
diminished PLPP3 activity may carry higher risk for developing com-
plications of atherosclerosis. In human lesions, the LPARs LPAR2,
LPAR5, and LPAR6 are expressed in ECs and regulate the response
to LPA-induced EC activation in advanced plaques. Low PLPP3
expression levels in plaques appear to increase the local accumulation
of the specific LPA molecular species (18:0). Our proposal is that this
phospholipid should be investigated as the plasma biomarker for risk
associated with low activity of LPP3 and, consequently, of LPA-
related receptor activation. Moreover, our findings open the possibil-
ities for investigations into the anti-atherosclerotic effects that may be
achieved by therapies aimed to (1) increase the levels of PLPP3, thus
reducing the levels of pro-inflammatory products; or (2) modulate the
activity of the LPA membrane receptor(s). The first option would24 Molecular Therapy: Methods & Clinical Development Vol. 10 September 2018require the development of therapeutic ap-
proaches for increasing the PLPP3 gene product
expression or the PLPP3 enzyme activity (i.e.,
localized gene therapy, modified RNA, or re-
combinant protein in stable liposomes).32 How-
ever, increasing PLPP3 expression is hazardous
as this enzyme hydrolyzes also S1P, which is
critical for lymphocyte egress and blood vessel
integrity. A high-affinity S1P receptor agonist
is currently in clinical development as an
immunomodulator for transplantation and
autoimmunity.33 Alternatively, modulation of
LPAR signaling, a target of known drug-treat-able class,15 would imply the development of more frequently used
therapeutic strategies, such as small molecules or biologicals.
MATERIALS AND METHODS
Human Material
Atherosclerotic plaques were obtained from patients undergoing sur-
gery for high grade (>50% North American Symptomatic Carotid
Endarterectomy Trial [NASCET])34 carotid stenosis at the Depart-
ment of Vascular Surgery, Karolinska University Hospital, Stock-
holm, Sweden, and clinical data were recorded upon admission.
Symptomatic patients (S) were defined based on the following symp-
toms: transitory ischemic attack (TIA), minor stroke, and amaurosis
fugax (AF). Patients without qualifying symptoms within 6 months
prior to surgery were categorized as asymptomatic (AS) and indica-
tion for CEA based on results from the Asymptomatic Carotid Sur-
gery Trial (ACST). A mandatory examination of the carotid arteries
(by duplex ultrasound [US] and/or computed tomography [CT] angi-
ography) was performed prior to surgery. Patients with severe
disability after major stroke were excluded since the remaining
cost-benefit of stroke prevention was limited and did not outweigh
the risk of surgery. In the study group, patients with atrial fibrillation
were also excluded in order to minimize analysis of carotid lesions in
patients with symptoms from cardioembolic rather than atheroem-
bolic origin.
Figure 7. Effect of PLPP3 and LPAR6 Silencing on Endothelial Cell Activation In Vitro
(A) Silencing of PLPP3 in cultured endothelial cells leads to induced mRNA expression of the inflammatory cytokines MCP1 and IL-6 and adhesion factors VCAM-1 and
ICAM-1 compared to control cells (scramble). No significant change in expression of LPARs 1–6 could be observed upon PLPP3 silencing. (B) Inhibition of LPAR6 alone had
no prominent effect on MCP1, IL-6, VCAM-1, or ICAM-1, but the upregulation of these genes caused in response to LPA stimulation (10 mM, 2-hr treatment) could be
significantly attenuated by simultaneous silencing of LPAR6. PLPP3 expression was not affected by LPA stimulation or the LPAR6 silencing. (C) Combined silencing of both
LPAR6 and PLPP3 did not result in any diminishing effects on endothelial activation compared to those already observed after silencing PLPP3 alone. Note also that neither
inhibition of PLPP3 nor LPA stimulation had any effect on the LPAR1 expression, but its induction was observed when LPAR6 was silenced. The expression of LPAR2 was
strongly enhanced after LPA stimulation alone, but not in combination with the inhibition of LPAR6 or PLPP3. Expression of LPAR4 was not affected in any of these ex-
periments. All experiments were repeated 4 times, n = 4 samples per group in all analyses. Significance indicated above bars calculated in comparison to scramble/control
cells (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
www.moleculartherapy.orgAs previously described,35 human carotid endarterectomy samples
(CPs) and blood were collected at surgery and retained within the
BiKE. NA controls were obtained from nine macroscopically
disease-free iliac arteries and one aorta from organ donors without
history of cardiovascular disease. The BiKE study is approved by
the Ethical Committee of Northern Stockholm with the following
ethical permits: EPN DNr 95-276/277; 02-146; 02-147, 2005/83-31;
2009/512-31/2; 2009/295-31/2; 2011/950-32; 2012/619-32; and 213/
2137-32. The project was performed under the Swedish biobank reg-
ulations, and prospective sampling was approved with informed con-
sent procedure (DNr 2009/512-31/2). BiKE is registered at Socialstyr-
elsen (The National Board of Health and Welfare) and Biobank of
Karolinska and approved by the Swedish Data Inspection Agency
(approval date/number 2002-09-30 DNr 916-2002). The BiKE data-
base was merged with the Swedish Hospital Discharge Register and
the Swedish Cause of Death Register for follow-up of major adverse
cardiovascular, cerebrovascular, and vascular events (MACCEs). All
samples were collected with informed consent from patients or organ
donor guardians.
This study involved 3 non-overlapping subsets of BIKE patients,
where 2 sets of plaques were analyzed by Affymetrix microarrays
(larger set with n = 127 plaques of which 87 were from S + 40
from AS patients and smaller set with n = 50 plaques where 40
from S + 10 from AS patients). DNA genotyping by Illumina chips
was carried out on patients from the larger subset (n = 127) and
used for eQTL analyses. The third subset of n = 18 BiKE plaques
(n = 9 from S + 9 from AS patients, matched for gender, age, and
statin medication) was analyzed using liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS) as previously described.35
For proteomic analyses, a central portion of the plaque correspond-
ing to the maximum stenosis was separated from the respectiveMolecular Thdownstream peripheral end (adjacent tissue) of the plaque and
used in comparisons. The BiKE study cohort demographics, details
of sample collection, processing, and analyses were as previously
described.36
Additional control vascular tissues (n = 23) and early fibroateroma le-
sions were obtained from the SOCRATES biobank (Leiden University
Medical Center, the Netherlands). Details of this biobank have been
described previously.37 Briefly, this biobank contains aortic wall
patches obtained during kidney transplantation with grafts derived
from cadaveric donors. All patches were from grafts that were eligible
for transplantation (i.e., all donors met the criteria set by The Euro-
transplant Foundation). Sample collection and handling were per-
formed in accordance with the guidelines of the Medical and Ethical
Committee in Leiden, the Netherlands, and the code of conduct of the
Dutch Federation of Biomedical Scientific Societies (https://www.
federa.org/?s=1&m=82&p=0&v=4#827).
Altogether, n = 33 NAs of different embryonic origins were used as
controls in this study. No additional demographic information is
available for these samples obtained from organ donors.
ISH
Chromogenic ISH for the detection of the LPAR mRNAs was per-
formed in a Ventana Discovery ULTRA instrument (Ventana Medi-
cal Systems, AZ, USA) using the ACD RNAscope 2.5 Red Kit
(Advanced Cell Diagnostics, Newark, CA, USA) and the mRNA
Discovery ULTRA RED 4.0 procedure. RNAscope 2.5 VS Probes
for Hs-LPAR1 (483889), Hs-LPAR2 (428809), Hs-LPAR3 (428819),
Hs-LPAR4 (458859), Hs-LPAR5 (#456369), and Hs-LPAR6
(409359) were designed by the probe manufacturer (Advanced Cell
Diagnostics). Formalin fixed paraffin embedded (FFPE) sectionserapy: Methods & Clinical Development Vol. 10 September 2018 25
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slides, and all operations, including baking, deparaffinization, condi-
tioning, pretreatment, ISH, and counterstaining using hematoxylin,
were performed in a Ventana Discovery ULTRA instrument.
Following the ISH procedure in the Ventana instrument, slides
were washed in lukewarm tap water with detergent until oil from
the slides was fully removed. Slides were finally washed in demineral-
ized water and allowed to air dry before mounting in EcoMount
mounting medium (Advanced Cell Diagnostics). Slides were subse-
quently inspected in bright-field microscopy using an AxioImager.Z1
microscope (Zeiss, Oberkochen, Germany), and digital images of
selected regions of interest were acquired using 40 and 63
objectives.
Double Staining by ISH Combined with Immunofluorescence
Non-decalcified FFPE sections (5 mm) from early fibroatheroma
lesion were used for co-staining of mRNA and protein markers.
First, as described in the previous section, ISH analyses were per-
formed for LPAR6 and PLPP3 mRNA using the Ventana Discovery
ULTRA instrument (Ventana Medical Systems, AZ, USA), the ACD
RNAscope 2.5 Red Kit (Advanced Cell Diagnostics, Newark, CA,
USA), and the mRNA Discovery ULTRA RED 4.0 procedure. Hs-
LPAR6 (409359) and Hs-PLPP3 (456371) for detection of mRNA
were designed by the probe manufacturer (Advanced Cell Diagnos-
tics). Second, following ISH and washes as previously described, two
slides each from LPAR6 and PPAP2B mRNA detection were stained
for CD34 and SMA, respectively. Briefly, slides were washed for
5 min in 1PBS, followed by blocking in 0.1 M Tris-HCl, 0.15 M
NaCl, 10% fetal bovine serum, and 0.01% Tween-20 for 15 min.
Anti-CD34 primary antibody (mAb mouse anti human CD34 Class
II clone QBEnd10, Dako, Glostrup, Denmark) diluted 1:100 and
anti-SMA primary antibody (rabbit mAb anti human SMA,
EPR5368, Abcam, Cambridge, UK) diluted 1:2,000, respectively,
were added and incubated 30 min at room temperature (RT). Slides
were washed three times in 1PBS, and then fluorophore-labeled
secondary antibodies were added. For detection of CD34, Alexa
Flour 488 Goat anti Mouse IgG(H+L) (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) (1:50) was added for 30 min
at RT. For detection of SMA, Alexa Flour 488 Goat anti Rabbit
IgG (H+L) (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA) (1:50) was added for 30 min at RT. Slides were washed
2 times in 1PBS and mounted with DAPI for epifluorescence mi-
croscopy inspection and imaging.
Lipid MSI In Situ
Snap-frozen human carotid plaque tissues were sectioned (12-mm
thickness) using cryostat CM3050S (Leica, Germany) and thaw
mounted on SuperFrost glass slide to enable multiple staining modal-
ities or on indium tin oxide (ITO) conductive glass slide for MSI ex-
periments and then dried in a vacuum chamber.38 Optimal cutting
temperature (OCT) compound was purchased from Fisher Scientific
(Illkirch, France). For the MALDI imaging experiment, two MALDI
matrices were used to enable the detection of lipid species, the 2,5-Di-
hydroxybenzoic acid (2,5-DHB) and the 9-aminoacridine (9AA,26 Molecular Therapy: Methods & Clinical Development Vol. 10 SeptemSigma-Aldrich, saint-quentin Fallavier, France) for positive and nega-
tive detection mode, respectively. 2,5-DHB powder (150 mg) was
used and vaporized on tissue sample using a home-built sublimation
apparatus (150C, 8min, 2.10–3mbar). 9AA solution was prepared at
10 mg/mL in methanol (MeOH)/water (7:3). The 9AA matrix solu-
tion was sprayed onto tissue sections using the SunCollect automatic
sprayer (SunChrom, Friedrichsdorf, Germany).
MS images were obtained using a SolariX MALDI-FTICR 7.0T
(Bruker Daltonics, Bremen, Germany) equipped with a Smartbeam
II laser used at a repetition rate of 1 kHz. Mass spectra were acquired
in the 100–1,200 m/z range in positive and negative detection mode
depending on MALDI matrix. The mass spectrum was obtained by
mass spectra average of 300 consecutive laser shots on the same loca-
tion, with a time domain of 1MWord, subsequent single zero filling,
and sine wave apodization. An image curve reduction (ICR) noise
threshold was fixed at 0.97 for imaging acquisition. An image raster
size of 30 mm was selected for human plaque tissues analysis.
FTMSControl 3.0 and FlexImaging 4.2 software packages (Bruker
Daltonics, Bremen, Germany) were used to control the mass and
set imaging parameters. The visualization and statistical analysis of
imaging data were performed using MultiImaging 1.1 software
(ImaBiotech, Lille, France). To combine and compare tissue staining
with the lipid distribution, MALDI imaging acquisition was per-
formed on adjacent carotid tissue sections and scanned using a 40
magnification objective on an Olympus IX18 microscope (Olympus,
Germany). Scans were then integrated in the MultiImaging software
for a co-registration with imaging data to accurately correlate the
distribution of molecular species with human plaque histological
regions. Assignment of lipid species was performed by searching
the accurate m/z values against the Lipidmap database using a mass
tolerance of 3 ppm.39
Bionformatics and Statistical Analyses
RNA extracted from endarterectomy (CP) and control NA specimens
was analyzed by Affymetrix microarrays. Robust multiarray average
(RMA) normalization and correction for batch effect was performed,
and processed gene expression data were returned in log2 scale. The
microarray dataset is available with the following accession number
from Gene Expression Omnibus: GSE21545. Target gene and protein
analyses were performed with GraphPad Prism 6 using a two-sided
Student’s t test assuming non-equal deviation. Pearson correlations
were calculated to determine the association between mRNA expres-
sion levels from microarrays, with Bonferroni correction for multiple
comparisons. Survival analysis was done using the Cox regression
model40 with event-free survival as the response variable and log2-
transformed gene expression levels as the explanatory variable. The
covariates age and gender were tested and had no effect on results. Re-
sults from qPCR were evaluated by multiple t tests assuming non-
equal deviation. In comparisons with more than two groups,
ANOVA was used as appropriate. In all analyses, p value < 0.05
was considered to indicate statistical significance.
Additional methods are described in the Supplemental Information.ber 2018
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